facebook
eISSN: 2084-9893
ISSN: 0033-2526
Dermatology Review/Przegląd Dermatologiczny
Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
1/2021
vol. 108
 
Share:
Share:
abstract:
Review paper

Metformin in skin diseases

Damian Kadylak
1
,
Karina Polak
1
,
Kamila Wojciechowska
1
,
Beata Bergler-Czop
2

1.
The Dermatology Ward of the Independent Public “A. Mielêcki” Teaching Hospital, Katowice, Poland
2.
Department of Dermatology, Silesian Medical University, Katowice, Poland
Dermatol Rev/Przegl Dermatol 2021, 108, 27-37
Online publish date: 2021/05/13
View full text Get citation
 
PlumX metrics:
Metformin is the most widely used oral antidiabetic drug in the world. It is the first-line drug in type 2 diabetes, where its inhibiting effect on hepatic glucose production, increasing muscle and adipose tissue insulin sensitivity and reduction of glucose absorption in the gut are used. Many benefits to the skin condition have been reported from using metformin in dermatological diseases such as acne vulgaris, hidradenitis suppurativa, hirsutism as well as reducing the risk of certain skin malignancies and the occurrence of psoriasis. Some adverse effects of metformin have also been reported: rash, skin allergic reactions, drug reaction with eosinophilia and systemic symptoms (DRESS syndrome), bullous pemphigoid, leukocytoclastic vasculitis, nail discoloration with subungual hyperkeratosis. The article is a review of currently available literature on the influence of metformin on the course of various skin diseases and its adverse effects.
keywords:

metformin, skin diseases, diabetes



Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.